By Dave Sebastian
Jazz Pharmaceuticals PLC said it has received approval from the U.S. Food and Drug Administration for Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.
Jazz said Rylaze was given an orphan drug designation for the treatment in June. It said it expects Rylaze to be commercially available in mid-July.
Write to Dave Sebastian at email@example.com
(END) Dow Jones Newswires
July 01, 2021 06:55 ET (10:55 GMT)Copyright (c) 2021 Dow Jones & Company, Inc.